Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Kailera Therapeutics, Inc. (KLRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13,52, with a market capitalisation of $1,78B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13,32 to $28,23. This page covers its latest market performance, valuation, price trends and company information.
$1,78B | |
$13,69 | |
$28,23 | |
$13,32 | |
$13,45 | |
-- | |
806,02K | |
-- | |
$28,23 | |
$13,32 | |
-- | |
-- |
Kailera Therapeutics, Inc. (KLRA) is trading at $13,52 in pre-market trading as of 2026-09-16 08:04:00, up 0,49% ($0,07) from the previous close of $13,45
Pre-market trading shows how investors are pricing KLRA before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Kailera Therapeutics, Inc. (KLRA) moved from $16,23 to $13,52, representing a decline of 16,72% ($2,71).
The stock traded between $13,32 and $16,63 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 763,52 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1,3%
KLRA is currently trading at $13,52, placing it 1,3% of the way from its 52-week low of $13,32 to its 52-week high of $28,23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kailera Therapeutics, Inc. (KLRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.